Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Alpha-Lipoic Acid (ALA) is supported by scientific evidence for use in peripheral neuropathy, particularly diabetic neuropathy. Several randomized controlled trials and meta-analyses have investigated ALA’s efficacy in reducing neuropathic symptoms such as pain, paresthesia, and numbness. The most robust evidence comes from studies conducted in Germany and other European countries, where intravenous (IV) administration of ALA (typically 600 mg/day) over 2-3 weeks has shown moderate improvements in neuropathic symptoms compared to placebo. Oral ALA has also been studied, with mixed but generally positive results for symptom relief, though the effects are less pronounced than with IV administration.

The proposed mechanism involves ALA’s antioxidant properties, which may help reduce oxidative stress implicated in nerve damage in diabetes and other neuropathies. Major guidelines in Europe, but not universally in the US, sometimes include ALA as an option for symptomatic relief in diabetic neuropathy. However, there is not unanimous agreement about its clinical significance, and the quality of evidence is moderate rather than high, with some concerns about study heterogeneity and methodological rigor. Nonetheless, ALA is not merely a traditional remedy; its use is grounded in clinical research, though its effect size and relevance to all forms of neuropathy remain somewhat limited.

More about Alpha-Lipoic Acid
More about Peripheral Neuropathy

Other ingredients used for Peripheral Neuropathy

Other health conditions supported by Alpha-Lipoic Acid

Products containing Alpha-Lipoic Acid